S-P's boceprevir reduces SVR after 28 weeks in Ph II study
US drug major Schering-Plough's boceprevir, its investigational oral hepatitis C protease inhibitor, significantly increased sustained virologic response rates with 28 and 48 weeks of therapy when added to the current standard of care, peginterferon and ribavirin for 48 weeks.
The results from this Phase II study in 595 treatment-naive patients with chronic hepatitis C virus genotype 1 were presented at the annual meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. Genotype 1 is the most common and hardest to treat form of HCV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze